TNRC6A

Across TCGA pan-cancer cohorts, TNRC6A mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TNRC6A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TNRC6A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TNRC6A is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, LUAD, and LSCC are the cancer types where TNRC6A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TNRC6A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.470	<.001	11	view →
LUAD	Male	II,III,IV	+0.442	<.001	9	view →
LSCC	Male	II,III,IV	+0.336	<.001	7	view →
PDAC	Male	II,III,IV	−0.268	.004	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TNRC6A–HNSC

Open the HNSC breakdown →